RT @IntFedAgeing: #DYK Biosimilars are emerging in the field of #Ophthalmology ? In this rapidly-changing health care landscape, #EyeSeeYou…

#DYK Biosimilars are emerging in the field of #Ophthalmology ? In this rapidly-changing health care landscape, #EyeSeeYou is keeping Canadians’ vision health top of mind! @FB_Canada @CCBWaterloo @CanadianOpto Read more: https://t.co/bTDVPBz4RA

RT @Vicente_MerinoB: Biosimilars in Ophthalmology: "Is There a Big Change on the Horizon?" - PubMed Labs https://t.co/njSlSRYJSE

Biosimilars in Ophthalmology: "Is There a Big Change on the Horizon?" - PubMed Labs https://t.co/njSlSRYJSE

RT @joaquinfdezoft: Biosimilares en #Oftalmología: "¿Un gran cambio en el horizonte?" (Cl Oph) "Las patentes en USA para #Ranibizumab y #A…

Biosimilares en #Oftalmología: "¿Un gran cambio en el horizonte?" (Cl Oph) "Las patentes en USA para #Ranibizumab y #Aflibercept caducarán en 2020 y sus patentes Europeas caducarán en 2022 y 2025" Acceso abierto: https://t.co/aXLzayEt6w

Biosimilars in #Ophthalmology: “Is there a big change on the horizon?” (Cl Oph) “The US patents for #Ranibizumab and #Aflibercept will expire in 2020 and their European patents will expire in 2022 and 2025” Open Access: https://t.co/aXLzayEt6w

Biosimilars in ophthalmology: “Is there a big change on the horizon?” https://t.co/fgRffFgOiK

Ophthopedia Update: Biosimilars in ophthalmology: “Is there a big change on the horizon?” https://t.co/08AFj3upqF #Ophthomology #AAO2018 #Ophthotwitter https://t.co/svZSMTAeCs